Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3

Rhea-AI Filing Summary

Kazia Therapeutics filed an initial ownership report for Chief Executive Officer John E. Friend II, showing he holds several option awards rather than recent market trades. These options give him the right to buy both American Depositary Shares (ADSs) and ordinary shares at preset prices before their expiration dates.

He holds ADS options over 30,000 ADSs at an exercise price of $0.3770 per ADS expiring on July 22, 2027, and over 500,000 ADSs at $6.5800 per ADS expiring on July 3, 2027. He also holds ordinary share options over 3,000,000 shares at $0.1323 per share expiring on May 3, 2027, and 1,000,000 ordinary shares at $0.1061 per share expiring on March 3, 2027.

Footnotes explain that these options vest in quarterly or annual installments starting between 2023 and 2025, subject to his continued service, and that exercise prices are reported in U.S. dollars based on a stated AUD/USD exchange rate. No purchases or sales occurred; this filing mainly outlines his existing equity-based compensation.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Friend John E. II

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Share Option (Right to Buy)	(1)	07/22/2027	American Depositary Shares(2)(3)	30,000	$0.377	D
American Depositary Share Option (Right to Buy)	(4)	07/03/2027	American Depositary Shares(2)(3)	500,000	$6.58	D
Ordinary Shares Option (Right to Buy)	(5)	05/03/2027	Ordinary Shares	3,000,000	$0.1323(6)	D
Ordinary Shares Option (Right to Buy)	(7)	03/03/2027	Ordinary Shares	1,000,000	$0.1061(6)	D

Explanation of Responses:

1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.

2. Each ADS option is convertible into ADSs upon exercise.

3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.

4. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.

5. The Ordinary Shares subject to the option ("OS option") vest in three equal annual installments beginning on May 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on May 3, 2023.

6. The exercise price is reported in U.S. dollars and reflects the conversion from AUD to USD at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026.

7. The Ordinary Shares subject to the OS option vest in two equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on March 3, 2023.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeffrey Bonacorda, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Kazia Therapeutics (KZIA) Form 3 filing show for CEO John E. Friend II?

The Form 3 shows CEO John E. Friend II’s existing option-based equity holdings, not new trades. He holds options over ADSs and ordinary shares with defined exercise prices, vesting schedules, and expirations, reflecting his equity compensation structure at Kazia Therapeutics.

How many American Depositary Shares options does the KZIA CEO hold according to this Form 3?

The CEO holds ADS options over 30,000 ADSs at $0.3770 per ADS and 500,000 ADSs at $6.5800 per ADS. These options expire in July 2027 and represent rights to acquire ADSs if exercised before expiration.

What ordinary share option positions are reported for Kazia Therapeutics (KZIA) CEO in this Form 3?

The filing reports ordinary share options over 3,000,000 ordinary shares at $0.1323 per share and 1,000,000 ordinary shares at $0.1061 per share. These options expire in May 2027 and March 2027, respectively, if not exercised.

Did the Kazia Therapeutics (KZIA) Form 3 disclose any stock purchases or sales by the CEO?

No, the Form 3 does not disclose stock purchases or sales. It lists existing option awards as holdings, with all transaction entries classified as holdings and no buy or sell transactions indicated in the transaction summary data.

How do the vesting schedules work for the KZIA CEO’s option awards in this filing?

Footnotes state the ADS and ordinary share options vest in equal quarterly or annual installments starting between 2023 and 2025, contingent on the CEO’s continuous service. This means the right to exercise portions of each option increases gradually over several years.

What is the relationship between Kazia Therapeutics ADSs and ordinary shares mentioned in the Form 3?

One footnote explains each ADS may be represented by 500 ordinary shares, upon surrender of the ADSs for the underlying ordinary shares. The ADSs themselves have no expiration date, though the options to purchase them do expire on specified future dates.